⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737160 | 1.00 | — | — | |
| SCHEMBL31637661 | 0.75 | — | — | |
| SCHEMBL1684155 | 0.72 | — | — | |
| SCHEMBL409307 | 0.72 | — | — | |
| SCHEMBL23489756 | 0.72 | APLNR (0.33) | — | |
| SCHEMBL22812495 | 0.71 | CYP17A1 (0.47) | — | |
| SCHEMBL29953246 | 0.70 | — | — | |
| SCHEMBL10188362 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL358759 | 0.69 | — | — | |
| SCHEMBL23704371 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250368646-A1 | TRICYCLIC FUSED WRN INHIBITORS | NIMBUS WADJET INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12459952-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| US-12421233-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250223293-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| US-12344609-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-1381590-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | Schering Corporation (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003057676-A1 | 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002083624-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| CN-1006792-B | PROCESS FOR PREPARING HYDROXY, ALKOXYPYRIMIDINE | PFIZER (US) | 1990-02-14 | — | — | CN | disclosed |
| CN-86104539-A | Hydroxyl and alkoxyl group miazines | — | 1987-01-21 | — | — | CN | disclosed |
| US-4127652-A | ARTHROPODICIDE, NEMATOCIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1978-11-28 | — | — | US | disclosed |